← Product Code [MQL](/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/MQL) · K080446 # RAPIDVIT AND RAPIDWARM CLEAVE (K080446) _Vitrolife Sweden AB · MQL · Nov 26, 2008 · Obstetrics/Gynecology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/MQL/K080446 ## Device Facts - **Applicant:** Vitrolife Sweden AB - **Product Code:** [MQL](/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/MQL.md) - **Decision Date:** Nov 26, 2008 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 884.6180 - **Device Class:** Class 2 - **Review Panel:** Obstetrics/Gynecology ## Indications for Use Rapid Vit™ Cleave is intended for vitrification of day 3 cleavage stage embryos RapidWarm™ Cleave is intended for warming of vitrified day 3 cleavage stage embryos ## Device Story RapidVit™ Cleave and RapidWarm™ Cleave are embryo-physiological solutions used in IVF laboratories. RapidVit™ Cleave utilizes cryoprotectants (1,2-propanediol, ethylene glycol) and sucrose to dehydrate day 3 cleavage stage embryos prior to cryopreservation. Embryos are plunged into liquid nitrogen to prevent ice crystal formation. RapidWarm™ Cleave is used for the subsequent warming of these vitrified embryos. The process is performed by embryologists in a clinical setting. The device enables embryo cryopreservation, allowing for future transfer and potentially improving patient outcomes in assisted reproductive technology. ## Clinical Evidence Clinical evidence provided via literature (Balaban et al. 2008) demonstrating successful vitrification of human cleavage stage embryos using the subject devices. ## Technological Characteristics Embryo-physiological solutions containing cryoprotectants (1,2-propanediol, ethylene glycol) and sucrose. Sterility assurance level 10^-6. Intended for manual laboratory use in cryopreservation workflows. ## Regulatory Identification Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.). ## Special Controls *Classification.* Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9. ## Predicate Devices - Vit Kit™ - Freeze and Vit Kit™ - Thaw from Irvine Scientific Co., Inc. ([K060168](/device/K060168.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # K 080446 #### X. PREMARKET NOTIFICATION SUMMARY . 1 NOV 2 6 2008 : | | NOV 26 2008 | |----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Submitted by: | Vitrolife Sweden AB
Box 9080
SE-400 92 Göteborg
SWEDEN | | Contact Person: | Mr Kjell Kjörk
Vitrolife Sweden AB
Box 9080
SE-400 92 Göteborg
SWEDEN
Phone +46 31 721 80 77
Fax +46 31 721 80 90
Mail kkjork@vitrolife.com | | Date Prepared: | 25 November 2008 | | Trade Name: | RapidVit™ Cleave
RapidWarm™ Cleave | | Common Name: | Vitrification freeze kit for cleavage stage embryos
Vitrification warming kit for cleavage stage
embryos | | Classification Name: | Reproductive Media and Supplements
(21 C.F.R. § 884.6180) | | Predicate Device: | Vit Kit™ - Freeze and Vit Kit™ - Thaw from Irvine
Scientific Co., Inc. (K060168) | | Description of the Device: | RapidVit™ Cleave is used for vitrification of day 3
cleavage stage embryos. The cryoprotectants 1,2-
propanediol and ethylene glycol are used together
with sucrose for dehydration of the embryo before
cryopreservation. Then the embryos are | : {1}------------------------------------------------ immediately plunged into liquid nitrogen in order to prevent intracellular and extracellular ice crystal formation. RapidWarm™ Cleave is used for the subsequent warming of vitrified day 3 cleavage stage embryos Intended Use: Rapid Vit™ Cleave is intended for vitrification of day 3 cleavage stage embryos RapidWarm™ Cleave is intended for warming of vitrified day 3 cleavage stage embryos #### Technological Characteristics: RapidVit™ Cleave and RapidWarm™ Cleave are devices used for vitrification of day 3 cleavage stage embryos. The cryoprotectants 1,2-propanediol and ethylene glycol are used together with sucrose for dehydration of the embryo before cryopreservation. Then the embryos are immediately plunged into liquid nitrogen in order to prevent intracellular and extracellular crystal formation. The predicate device Vit Kit™ - Freeze/Vit Kit™ - Thaw and RapidVit™ Cleave/RapidWarm™ Cleave are embryo-physiological solutions supplemented with permeable and non-permeable cryoprotectants. Both devices are subject to the same control methods and, to a significant degree, contain the same components. They have similar handling procedures and the same sterility assurance level (10") and storage conditions. The main differences between RapidVit™ Cleave and RapidWarm™ Cleave and Vit Kit™ - Freeze and Vit Kit™ - Thaw are the following: - Vit Kit™ Freeze and Vit Kit™ Thaw contain ethylene glycol, DMSO and . sucrose as cryoprotectants, while RapidVit™ Cleave and RapidWarm™ Cleave contain ethylene glycol, 1,2-propanediol and sucrose - Vit Kit™ Freeze and Vit Kit™ Thaw is intended for blastocysts stage . embryos while RapidVit™ Cleave and RapidWarm™ Cleave is intended for cleavage stage embryos Successful vitrification of human cleavage stage embryos by use of RapidVit™ Cleave and RapidWarm™ Cleave has been clinically proven (Balaban et al. 2008). {2}------------------------------------------------ #### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized graphic of three overlapping shapes resembling a person with outstretched arms, positioned to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the graphic. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Kjell Kjörk Pharmacist, Regulatory Affairs Manager Vitrolife Sweden AB Faktorvägen 13 SE-434 37 Kungsbacka SWEDEN **NOV 26 2006** K080446 Re: > Trade/Device Name: RapidVit™ Cleave RapidWarm" Cleave Regulation Number: 21 CFR §884.6180 Regulation Name: Reproductive media and supplements Regulatory Class: II Product Code: MQL Dated: November 10, 2008 Received: November 12, 2008 Dear Mr. Kjörk: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ #### Page 2 Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter: | 21 CFR 876.xxx | (Gastroenterology/Renal/Urology) | 240-276-0115 | |----------------|----------------------------------|--------------| | 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-0115 | | 21 CFR 894.xxx | (Radiology) | 240-276-0120 | | Other | | 240-276-0100 | Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Jozpu M. Whang Joyce M. Whang, Ph.D. Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## K080446 ### XI. INDICATIONS FOR USE STATEMENT 510(k) Number (if known): K080446 Device Name: RapidVit™ Cleave RapidWarm™ Cleave Indications for Use: RapidVit™ Cleave is indicated for vitrification of day 3 cleavage stage embryos RapidWarm™ Cleave is indicated for warming of vitrified day 3 cleavage stage embryos RapidVit™ Cleavage and RapidWarm™ Cleavage are restricted to sale by or on the order of a physician. #### (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 C.F.R. § 801.109) OR Over-the Counter Use (Division Sign-Off) (Division of Reproductive, Abdominal and Radiological Devices 510(k) Number --- **Source:** [https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/MQL/K080446](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/MQL/K080446) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com